ACURATE neo™
Aortic Valve System
Explore
SAVI-TF Post-Market Registry
in the SAVI-TF registry
- Möllmann H et al.; EuroIntervention 2018;13:e1764-e1770
One-year outcomes of the european post-market registry using the ACURATE neo transcatheter heart valve under real world conditions in 1,000 patients
- Kim et al.; JACC: Cardiovascular Interventions vol. 11, no.1 4, 2 0 1 8; July 23, 2018: 1368–74
25 centers in Europe directly following CE-marking of ACURATE neo between
October 2014 and April 2016.
Confirmed safety and performance:
- Strong safety and effectiveness data
- Very low complication and pacemaker rates
- Low mortality and excellent hemodynamic performance
Outcomes¹
SAVI-TF RESULTS SUMMARY
(% of patients)
HEMODYNAMIC PERFORMANCE
(mmHg/cm2)
Clinical data presentation – TCT 2017
"ACURATE neo TF Valve: Review of the Device and the SAVI-TF1000 Data"
Prof. Dr. Helge Möllmann
Dortmund, Germany
ACURATE neo TA CE-Mark Study
Conradi L., Hilker M., Kempfert J., Börgermann J., Treede H., Holzhey DM. et al. Eur J Cardiothorac Surg 2018; doi:10.1093/ejcts/ezy097.
ACURATE neo demonstrated:
- Safety and efficacy in patients with severe symptomatic aortic stenosis and high surgical risk, ineligible for transfemoral access
- High device and procedural success, short implantation times and a low rate of access site related complications
High device & procedural success
98.3%
Procedural/device success
3:00
Average device usage time
5.9 mmHg
Mean transvalvular gradients at 30 days
ACURATE neo TA SAFETY & PERFORMANCE
(% of patients unless otherwise stated)
ECHOCARDIOGRAPHIC FOLLOW-UP
NYHA CLASSIFICATION
